Independent Advisor Alliance Incyte Corp Transaction History

Independent Advisor Alliance

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $198,750 - $243,408	2,830 New	2,830 $204,000
Q2 2022 Aug 04, 2022	BUY	$66.18 - $83.18 $10,919 - $13,724	165 Added 5.99%	2,918 $222,000
Q1 2022 May 06, 2022	BUY	$66.02 - $79.71 $181,753 - $219,441	2,753 New	2,753 $219,000
Q2 2018 Aug 08, 2018	SELL	$60.85 - $83.98 $377,635 - $521,179	-6,206 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $515,470 - $626,681	6,206 New	6,206 $500,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Independent Advisor Alliance, based on Form 13F filings with the SEC.

Stay updated on Independent Advisor Alliance with notifications on news.